2 days ago
Barrington Lifts PT on Orthofix Medical (OFIX) to $17 From $16, Keeps an Overweight Rating
Orthofix Medical Inc. (NASDAQ:OFIX) is one of the . Barrington analyst Michael Petusky raised the firm's price target on Orthofix Medical Inc. (NASDAQ:OFIX) to $17 from $16 on August 6, keeping an Outperform rating on the shares.
A surgeon using a bone growth stimulator device in a modern operating theatre.
The analyst told investors in a research note that Orthofix Medical Inc. (NASDAQ:OFIX) reported strong fiscal Q2 results and affirmed its 2025 outlook, supporting the optimistic rating.
Orthofix Medical Inc. (NASDAQ:OFIX) announced its fiscal Q2 2025 results on August 5, reporting net sales of $203.1 million for the quarter, representing a 2% growth on a reported basis and 4% on a pro forma constant currency basis compared to Q2 2024.
U.S. Spine Fixation underwent a net sales growth of 5% and procedure volume growth of 7% compared to the same quarter last year, while Bone Growth Therapies' net sales reached $62.6 million, representing growth of 6%.
Orthofix Medical Inc. (NASDAQ:OFIX) provides medical devices and operates through the Global Spine and Global Extremities business segments. Its Global Spine reporting segment encompasses three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics.
While we acknowledge the potential of OFIX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
